Business News • PR NewsWire • Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

CHICAGO and RARITAN, N.J., June 4, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced new data from updated analyses of the pivotal Phase 3 CASTOR and POLLUX clinical studies, demonstrating that DARZALEX® (daratumumab) in combination with bortezomib and...

View More : http://www.prnewswire.com/news-releases/daratumumab-combination-therapy-improved-clinical-outcomes-regardless-of-cytogen...

Releted News by prnewswire

U.S. Census Bureau Daily Feature for June 4: Patently Precocious

Honda Sweeps Opening Race in Detroit

Acura Wins in the Motor City

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting